Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06350825
PHASE3

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Sponsor: The First Affiliated Hospital with Nanjing Medical University

View on ClinicalTrials.gov

Summary

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Official title: Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2016-01-01

Completion Date

2028-12-31

Last Updated

2024-04-05

Healthy Volunteers

No

Interventions

PROCEDURE

Cytoreductive prostatectomy or brachytherapy

local treatment+SOC for metastatic prostate cancer

DRUG

ADT+second-generation antiandrogens ± chemotherapy

SOC(Triplet or doublet therapy) for mHSPC

Locations (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China